173 related articles for article (PubMed ID: 31916)
1. Properties of immobilized fig alpha-galactosidase and effect on ceramide-3 content of plasma from patients with Fabry's disease.
Schram AW; Hamers MN; Oldenbroek-Haverkamp E; Strijland A; de Jonge A; van den Bergh FA; Tager JM
Biochim Biophys Acta; 1978 Dec; 527(2):456-64. PubMed ID: 31916
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting the hydrolysis of ceramide-3 by alpha-galactosidase A from human liver.
Schram AW; Hamers MN; Samson MR; Cordus S; De Jonge A; Brown I; Robinson D; Tager JM
Biochim Biophys Acta; 1979 May; 568(1):59-70. PubMed ID: 36166
[TBL] [Abstract][Full Text] [Related]
3. Relationship of the multiple forms of human alpha-D-galactosidase and alpha-D-fucosidase in the normal and in Fabry's disease.
Beyer E; Schono N; Kozlova I; Wiederschain G
Biochim Biophys Acta; 1990 May; 1038(3):386-9. PubMed ID: 2160280
[TBL] [Abstract][Full Text] [Related]
4. The fate of internalized alpha-2-macroglobulin: alpha-galactosidase conjugate in fibroblasts from Fabry's hemizygote.
Osada T; Kuroda Y; Ikai A
Biochem Biophys Res Commun; 1987 Mar; 143(3):954-8. PubMed ID: 2436620
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathology of Fabry's disease. Physical and kinetic properties of alpha-galactosidase A in cultured human endothelial cells.
Johnson DL; Desnick RJ
Biochim Biophys Acta; 1978 Jan; 538(2):195-204. PubMed ID: 23178
[No Abstract] [Full Text] [Related]
6. Fabry's disease with partially deficient hydrolysis of ceramide trihexoside.
Kobayashi T; Kira J; Shinnoh N; Goto I; Kuroiwa Y
J Neurol Sci; 1985 Feb; 67(2):179-85. PubMed ID: 2984338
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of ceramide trihexoside in cultured skin fibroblasts from Fabry's patients, carriers and normal controls.
Kobayashi T; Shinnoh N; Kuroiwa Y
J Neurol Sci; 1984 Aug; 65(2):169-77. PubMed ID: 6090593
[TBL] [Abstract][Full Text] [Related]
8. Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease.
Mayes JS; Scheerer JB; Sifers RN; Donaldson ML
Clin Chim Acta; 1981 May; 112(2):247-51. PubMed ID: 6263521
[TBL] [Abstract][Full Text] [Related]
9. Decline of plasma brain natriuretic peptide during enzyme replacement therapy in a female patient with heterozygous Fabry's disease.
Masugata H; Senda S; Goda F; Yamagami A; Okuyama H; Kohno T; Hosomi N; Yukiiri K; Noma T; Murao K; Kohno M; Itoh S
Tohoku J Exp Med; 2009 Mar; 217(3):169-74. PubMed ID: 19282651
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast alpha-galactosidase A activity for identification of Fabry's disease heterozygotes.
Fensom AH; Benson PF; Grant AR; Jacobs L
J Inherit Metab Dis; 1980; 2(1):9-12. PubMed ID: 6273649
[TBL] [Abstract][Full Text] [Related]
11. Preparation and properties of alpha-galactosidase chemically attached to activated chitin.
Onal S; Telefoncu A
Artif Cells Blood Substit Immobil Biotechnol; 2003 Aug; 31(3):339-55. PubMed ID: 12906314
[TBL] [Abstract][Full Text] [Related]
12. Loss of electron-dense lamellar material from Fabry's disease fibroblasts after enzyme replacement.
Sifers RN; Mayes JS; Nordquist RE
Hum Genet; 1983; 65(1):85-7. PubMed ID: 6315565
[TBL] [Abstract][Full Text] [Related]
13. alpha-galactosidase A from human placenta. Stability and subunit size.
Mayes JS; Beutler E
Biochim Biophys Acta; 1977 Oct; 484(2):408-16. PubMed ID: 71921
[TBL] [Abstract][Full Text] [Related]
14. Failure to correct the metabolic defect by renal allotransplantion in Fabry's disease.
Spence MW; MacKinnon KE; Burgess JK; d'Entremont DM; Belitsky P; Lannon SG; MacDonald AS
Ann Intern Med; 1976 Jan; 84(1):13-6. PubMed ID: 812404
[TBL] [Abstract][Full Text] [Related]
15. [Substrate specificity of multiple forms of human alpha-D-galactosidase and alpha-D-fucosidase].
Baskaeva EM; Shono NI; Kozlova IK; Vidershaĭn GIa
Biokhimiia; 1989 Mar; 54(3):421-6. PubMed ID: 2546612
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of neutral glycosphingolipids in plasma of a normal human and a patient with Fabry's disease.
Vance DE; Krivit W; Sweeley CC
J Biol Chem; 1975 Oct; 250(20):8119-25. PubMed ID: 809441
[TBL] [Abstract][Full Text] [Related]
17. [Biochemical and pathological studies on a carrier of Fabry's disease manifesting bouts of pain in the extremities].
Katayama M; Kobayashi T; Ohnishi A; Goto I; Kuroiwa Y
Rinsho Shinkeigaku; 1984 Jun; 24(6):575-80. PubMed ID: 6094070
[No Abstract] [Full Text] [Related]
18. Residual activity of alpha-galactosidase A in Fabry's disease.
Romeo G; D'Urso M; Pisacane A; Blum E; De Falco A; Ruffilli A
Biochem Genet; 1975 Oct; 13(9-10):615-28. PubMed ID: 812485
[TBL] [Abstract][Full Text] [Related]
19. Variables in the laboratory diagnosis of Fabry's disease by measurement of methylumbelliferyl-alpha-galactosidase activity.
Brewster MA; Whaley SA; Kane AC
Clin Chem; 1974 Mar; 20(3):383-6. PubMed ID: 4205035
[No Abstract] [Full Text] [Related]
20. [Biochemical studies in Fabry's disease (author's transl)].
Handa S
Nihon Jinzo Gakkai Shi; 1978 Nov; 20(11):1212-4. PubMed ID: 219278
[No Abstract] [Full Text] [Related]
[Next] [New Search]
